Congruence Therapeutics: Valuation, Funding & Investors
Congruence Therapeutics is a computationally-driven biotechnology company focused on developing transformative small molecule correctors to address diseases caused by protein misfolding. Utilizing its proprietary Revenir™ drug discovery platform, Congruence is advancing a pipeline targeting high-value, genetically validated, and difficult-to-drug conditions such as MC4R-deficient genetic obesity, GBA1-driven Parkinson's disease, and Alpha-1 Antitrypsin Deficiency. The company collaborates with large pharmaceutical partners to discover treatments for solid tumors and metabolic diseases, leveraging its innovative approach to drug discovery.
Leadership & Board
Latest Estimated Valuation
- Total Amount Raised
- $72M
- Total Funding Rounds
- 2
- Latest Funding Amount
- $40M
- Latest Funding Round
- Investment
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Mar 19, 2026 | Investment | $39.50M | ― |
| Sep 04, 2025 | Investment | $32.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| OrbiMed | Investment |
| Amplitude Ventures | Investment |
| Investissement Quebec | Investment |
| FSTQ | Investment |
| Lumira | Investment |
| BDC Capital's Thrive Venture Fund | Investment |
| Driehaus | Investment |
| Silver Arc | Investment |
Similar Companies
A snapshot of private companies similar to Congruence Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis
